Biotech Stocks Touching New Lows: Reliv International (NASDAQ:RELV), Can Fite Biopharma (NYSEMKT:CANF), Enzymotec (NASDAQ:ENZY), Pacific Biosciences (NASDAQ:PACB)

An increase in European and U.S. sales helped Reliv International Inc. (NASDAQ:RELV) raise profits by a small amount in the fourth quarter. Reliv International, Inc (NASDAQ:RELV) stock performance was -11.60% in last session and finished the day at $2.03. Traded volume was 64,448.00million shares in the last session and the average volume of the stock remained 10.29K shares. The beta of the stock remained 1.35. Reliv International, Inc (NASDAQ:RELV) insider ownership is 36.99%.

Can-Fite BioPharma Ltd. (ADR) (AMEX:CANF) announced that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) dropped -5.47 percent to $5.53 yesterday on volume of 24.82K shares. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) has a market capitalization of $37.55million.

Enzymotec Ltd (NASDAQ:ENZY) sports a Zacks Rank #1 (Strong Buy), Covidien and Stryker bear a Zacks Rank #2 (Buy). Enzymotec Ltd (NASDAQ:ENZY)’s stock on Mar 10, 2014 reported a decrease of -5.94% to the closing price of $25.96. Its fifty two weeks range is $14.25 -$35.12. The total market capitalization recorded $564.90million. The overall volume in the last trading session was 157,278.00million shares. In its share capital, ENZY has 21.55million outstanding shares.

Pacific Biosciences of California (NASDAQ:PACB) has been awarded US Patent No. 8,658,365, “Nucleic acid synthesis compositions and methods and systems for using same.” On Monday, shares of Pacific Biosciences of California (NASDAQ:PACB) dropped -6.97% to close the day at $6.20. Company return on investment (ROI) is -91.00% and its monthly performance is recorded as -1.97%. Pacific Biosciences of California (NASDAQ:PACB) quarterly revenue growth is 41.02%.